Rule-Out Cutoff of Two-Dimensional Shear Wave Elastography for Significant Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: Systematic Review, Meta-Analysis, and External Validation.

Clin Gastroenterol HepatolJun 2, 2026 (epub)
Clinical ResearchGastroenterology

Joo Hyun Oh, Jonghyun Lee, Miyoung Choi et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the diagnostic performance of two-dimensional shear-wave elastography for detecting significant fibrosis (≥F2) in 3171 adults with metabolic dysfunction-associated steatotic liver disease. The study identified a rule-out cutoff of 6.6 kPa, achieving a sensitivity of 80.0% and specificity of 70.7%, indicating its potential utility in clinical practice.

Key findings

  • The summary area under the receiver operating characteristic curve was 0.84 (95% CI, 0.81-0.87).
  • A liver stiffness cutoff of 6.6 kPa achieved a sensitivity of 80.0% and specificity of 70.7%.
  • Negative predictive value exceeded 95% at prevalences of 5% and 10%.
  • External validation showed sensitivity of 0.86 and specificity of 0.68.

Why it matters

Accurate assessment of liver fibrosis is crucial for managing metabolic dysfunction-associated steatotic liver disease. The identified cutoff can help clinicians rule out significant fibrosis, potentially improving patient outcomes through timely interventions.

Source

Published in Clin Gastroenterol Hepatol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.